A Review on Prevention of Hepatitis B with the Hepatitis B Vaccine

Abstract

Around 350 million people worldwide are infected with HBV, which is a leading cause of end-stage liver failure, hepatocellular cancer, and mortality. New therapeutic treatments have increased the number of HBV treatment options available, but since current medications are usually used for the remainder of one's life, getting the best start is crucial. After obtaining a positive pregnancy test results, a 25-year-old registered nurse pays a visit to begin prenatal care. She says that when she was given hepatitis B vaccine by her present job, she rejected it since she does not take blood and therefore does not consider herself at danger of infection. The age at the time of infection has an inverse relationship with the likelihood of developing a chronic carrier status. Infected newborns have a 90 percent chance of developing chronic carriage. In medical settings, improved disposal of needles and other sharp items, as well as innovative technologies intended to minimize the danger of accidental needle jabs, have reduced exposures.